Tango Adds $60M in CRISPR Hunt for Synthetically Lethal Cancer Drugs

Tango Adds $60M in CRISPR Hunt for Synthetically Lethal Cancer Drugs

Source: 
Xconomy
snippet: 

CRISPR is key to the cancer drugs that Tango Therapeutics is developing, but the startup isn’t out to edit disease-causing genes. Tango uses technology as a tool for finding drug targets, in research that has yielded a pipeline of compounds. Now it has $60 million to continue that work.